Pfizer

Pfizer to Market Viagra Through Roman's Telehealth Service
Pfizer to Market Viagra Through Roman's Telehealth Service
Motley Fool
Pfizer
Roman
Ro
generics
Viagra
erectile dysfunction
telehealth
digital health
Greenstone
Flag link:
GlaxoSmithKline halts Excedrin production over manufacturing stumble
GlaxoSmithKline halts Excedrin production over manufacturing stumble
Fierce Pharma
GSK
consumer health
Pfizer
Excederin
drug manufacturing
Flag link:
Pfizer teams up with Insilico to mine data for drug targets
Pfizer teams up with Insilico to mine data for drug targets
Fierce Biotech
Pfizer
R&D
Insilico
real world evidence
RWE
Flag link:
GSK, Pfizer contradict on the future of consumer health JV — report
GSK, Pfizer contradict on the future of consumer health JV — report
Endpoints
GSK
Pfizer
consumer health
JPMHC 2020
Flag link:
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Fierce Biotech
Biogen
Alzheimer's disease
Pfizer
PF-05251749
Flag link:
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
EP Vantage
Pfizer
abrocitinib
Dupixent
Sanofi
Myovant
Relugolix
uterine fibroids
Flag link:
Pfizer may look messy post-Upjohn spinoff, but better days could be ahead: analyst
Pfizer may look messy post-Upjohn spinoff, but better days could be ahead: analyst
Fierce Pharma
Pfizer
Upjohn
Mylan
spinoffs
generics
Flag link:
Pfizer and eFFECTOR Ink $507 Million Cancer Deal
Pfizer and eFFECTOR Ink $507 Million Cancer Deal
BioSpace
Pfizer
Effector
small molecule drugs
cancer
drug development
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Endpoints
Merck KGaA
Pfizer
Bavencio
bladder cancer
FDA
Flag link:
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
EP Vantage
Karyopharm
Xpovio
Multiple Myeloma
Pfizer
Akcea
Ionis Pharmaceuticals
AKCEA-ANGPTL3-Lrx
Flag link:
Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China
Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China
Fierce Pharma
Pfizer
Merck
Prevnar 13
Gardasil
vaccines
China
Walvax
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Fierce Pharma
drug pricing
Pfizer
Bristol-Myers Squibb
AbbVie
Flag link:
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
Endpoints
Pfizer
Bristol-Myers Squibb
FDA
generics
bloodthinners
Eliquis
Micro Labs
Mylan
Flag link:
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
BioSpace
Pfizer
Theravance
JAK inhibitors
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
Exact Sciences Should Benefit from Pfizer’s News Today
Exact Sciences Should Benefit from Pfizer’s News Today
Motley Fool
Pfizer
colorectal cancer
EXACT Sciences
FDA
Braftovi
Cologuard
Flag link:
As NASH shifts again, the focus remains on Genfit’s big readout
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Flag link:
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
JNJ
Erleada
FDA
Flag link:

Pages